Trial Profile
Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Fluorouracil; Levofolinic acid; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 05 Jun 2018 Results (n=27) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Status changed from recruiting to active, no longer recruiting, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 21 Jan 2017 Status changed from not yet recruiting to recruiting, according to the results presented at the 2017 Gastrointestinal Cancers Symposium.